Recent news on Laronidase

BioMarin Submits New Drug Application for US Marketing ...  -  25 May 2007
PR Newswire (press release),...and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme

Genzyme Reports Significant Revenue and Earnings Growth in First ...  -  Apr 25, 2007
WebWire (press release),Sales of Aldurazyme® (laronidase) for MPS I grew 26 percent to $26.8 million, compared with $21.3 million in last year’s first quarter.

Genzyme Reports Significant Revenue and Earnings Growth in First ...  -  26 Apr 2007
WebWire (press release),Sales of Aldurazyme® (laronidase) for MPS I grew 26 percent to $26.8 million, compared with $21.3 million in last year’s first quarter.

BioMarin Announces Closing of $324875000 Public Offering of Senior ...  -  Apr 24, 2007
PharmaLive.com (press release),...and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme

BioMarin to Host First Quarter 2007 Financial Results Conference ...  -  Apr 20, 2007
PharmaLive.com (press release),...and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme

BioMarin Announces Date and Time Change of Fourth Quarter and Full ...  -  Feb 19, 2007
Drug Newswire (press release),...and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme

BioMarin to Host Fourth Quarter and Full Year 2006 Financial ...  -  Feb 15, 2007
Yahoo! News (press release)...a product wholly developed and commercialized by BioMarin, and Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin

BioMarin Announces Fourth Quarter and Full Year 2006 Financial Results  -  Feb 20, 2007
PR Newswire (press release),Net sales of Aldurazyme(R) (laronidase), an enzyme replacement therapy for mucopolysaccharidosis I, (MPS I) by BioMarin/Genzyme LLC increased by

Remaining $51.4 Million of Convertible Notes Due 2008 Converted ...  -  Jan 30, 2007
PharmaLive.com (press release),...a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product that BioMarin

Largest-ever Fabry study shows earlier treatment with (Pr ...  -  Jan 16, 2007
CNW Telbec (Communiqués de presse),These include Cerezyme(R) (imiglucerase) for the treatment of Type 1 and Type 3 Gaucher disease and Aldurazyme(R) (laronidase) for the treatment of MPS I,

Genzyme Reports Strong Fourth-Quarter Revenue Growth to Conclude ...  -  Jan 10, 2007
Oxfordshire Bioscience Network (press release),Sales of Aldurazyme® (laronidase) enzyme replacement therapy for MPS I were $27 million in the fourth quarter, compared with $21 million in the same quarter

BioMarin to Present at the JPMorgan 25th Annual Healthcare Conference  -  Jan 8, 2007
PharmaLive.com (press release),...and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme

BioMarin to Present at the JPMorgan 25th Annual Healthcare Conference  -  Jan 7, 2007
Yahoo! News (press release)...a product wholly developed and commercialized by BioMarin, and Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin

BioMarin Calls Remaining $51.4 Million of Convertible Notes Due 2008  -  Dec 27, 2006
Drug Newswire (press release),...a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product that BioMarin

Parents win fight for girl’s £100000 NHS treatment  -  Dec 8, 2006
The Herald,The Scottish Medicines Consortium had recommended against prescribing the drug laronidase, an enzyme replacement therapy. The health board then refused to

The correct outcome  -  Dec 8, 2006
The Herald,The refusal was on the basis that the treatment, using the drug Laronidase, had not been sanctioned by the Scottish Medicines Consortium (SMC),

HAYLEIGH JOY OVER U-TURN BY NHS  -  Dec 8, 2006
Glasgow Daily Record,NHS Greater Glasgow and Clyde initially said they would not pay for laronidase, a costly enzyme-replacement therapy available in England.

Parents wait for Hayleigh decision  -  Dec 8, 2006
Glasgow Evening Times,NHS Greater Glasgow and Clyde initially said it would not pay for Laronidase, an enzyme-replacement therapy, costing £100000 a year.

BioMarin Calls Remaining $51.4 Million of Convertible Notes Due 2008  -  Dec 22, 2006
PR Newswire (press release),...a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product that BioMarin

First Therapy Ever Approved in Canada for Ultra-Rare Form of ...  -  Dec 8, 2006
DG NewsPrCerezyme® (imiglucerase) for Type 1 and Type 3 Gaucher disease and, in collaboration with BioMarin Pharmaceutical Inc., PrAldurazyme® (laronidase) for

First Therapy Ever Approved in Canada for Ultra-Rare Form of ...  -  Dec 7, 2006
CNW Telbec (Communiqués de presse),BioMarin Pharmaceutical Inc., PrAldurazyme(R) (laronidase) for MPS I. NOTE: Doctors and patients are available for interviews in English and French.

Companies Rely on RCT Protein Expression Technology to Make ...  -  Nov 27, 2006
PharmaLive.com (press release),...a receptor fusion protein therapy for rheumatoid arthritis, and Aldurazyme(R) (laronidase), an enzyme-replacement therapy developed and commercialized

Companies Rely on RCT Protein Expression Technology to Make ...  -  Nov 27, 2006
Business Wire (press release),...and Aldurazyme ® (laronidase), an enzyme-replacement therapy developed and commercialized through a collaboration between BioMarin Pharmaceutical Inc.

BioMarin Announces Third Quarter 2006 Financial Results  Nov 1, 2006
Net sales of Aldurazyme(R) (laronidase), an enzyme replacement therapy for mucopolysaccharidosis I, (MPS I) by BioMarin/Genzyme LLC increased by approximately ... -PR Newswire (press release), BioMarin Announces Marketing Approval for Aldurazyme in Japan  Oct 31, 2006
BMRN) announced today that Japan's Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for Aldurazyme(R) (laronidase), the first ... -Drug Newswire (press release), BioMarin to Present at the Cowen and Company 7th Annual Global ...  Nov 2, 2006
...for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I ... -Earthtimes.org Market Report -- In Play (BMRN)  Oct 31, 2006
Aldurazyme in Japan Co announces that Japan's Ministry of Health, Labor, and Welfare has granted marketing authorization for Aldurazyme (laronidase), the first ... -MSN Money Genzyme, Now In Front For AnorMED, Reports Earnings  Oct 13, 2006
...replacement therapies grew at a more dramatic rate: Fabrazyme (agalsidase beta) climbed to $93.2 million, up 18 percent, Aldurazyme (laronidase) reached $25 ... -BioWorld Online, Genzyme Reports Strong Third-Quarter Financial Results  Oct 12, 2006
Sales of Aldurazyme® (laronidase) enzyme replacement therapy for patients with MPS I also continue to track with expectations, rising to $25.0 million in the ... -Yahoo! News (press release) Genzyme Reports Strong Third-Quarter Financial Results  Oct 12, 2006
Sales of Aldurazyme(R) (laronidase) enzyme replacement therapy for patients with MPS I also continue to track with expectations, rising to $25.0 million in the ... -Drug Newswire (press release), BioMarin Completes Enrollment of Phase 2 Clinical Study of 6R-BH4 ...  Sep 21, 2006
...for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I ... -PipelineReview.com

Amicus Therapeutics Raises $60 Million Series D Financing Company ...  Sep 14, 2006
Mr. Patterson oversaw the development of Aldurazyme® (laronidase) for the treatment of the genetic disease MPS I and helped build the sales and marketing ... -Yahoo! News

Parents win fight for girl’s £100000 NHS treatment  -  Dec 8, 2006
The Herald,The Scottish Medicines Consortium had recommended against prescribing the drug laronidase, an enzyme replacement therapy. The health board then refused to

The correct outcome  -  Dec 8, 2006
The Herald,The refusal was on the basis that the treatment, using the drug Laronidase, had not been sanctioned by the Scottish Medicines Consortium (SMC),

HAYLEIGH JOY OVER U-TURN BY NHS  -  Dec 8, 2006
Glasgow Daily Record,NHS Greater Glasgow and Clyde initially said they would not pay for laronidase, a costly enzyme-replacement therapy available in England.

Parents wait for Hayleigh decision  -  Dec 8, 2006
Glasgow Evening Times,NHS Greater Glasgow and Clyde initially said it would not pay for Laronidase, an enzyme-replacement therapy, costing £100000 a year.

Schoolgirl, 8, is only child in UK denied therapy  -  Nov 21, 2006
The Herald,It said the Scottish Medicines Consortium had recommended against prescription of the drug Laronidase in NHS Scotland.

NHS board reviews girl's therapy  -  Nov 20, 2006
BBC News,Her parents said she was the only patient in the UK to be refused therapy with the drug Laronidase, and that she may have to go to England for treatment.

First Therapy Ever Approved in Canada for Ultra-Rare Form of ...  -  Dec 8, 2006
DG NewsPrCerezyme® (imiglucerase) for Type 1 and Type 3 Gaucher disease and, in collaboration with BioMarin Pharmaceutical Inc., PrAldurazyme® (laronidase) for

First Therapy Ever Approved in Canada for Ultra-Rare Form of ...  -  Dec 7, 2006
CNW Telbec (Communiqués de presse),BioMarin Pharmaceutical Inc., PrAldurazyme(R) (laronidase) for MPS I. NOTE: Doctors and patients are available for interviews in English and French.

Companies Rely on RCT Protein Expression Technology to Make ...  -  Nov 27, 2006
PharmaLive.com (press release),...a receptor fusion protein therapy for rheumatoid arthritis, and Aldurazyme(R) (laronidase), an enzyme-replacement therapy developed and commercialized

Companies Rely on RCT Protein Expression Technology to Make ...  -  Nov 27, 2006
Business Wire (press release),...and Aldurazyme ® (laronidase), an enzyme-replacement therapy developed and commercialized through a collaboration between BioMarin Pharmaceutical Inc.

Board think again on Hayleigh's illness  -  Nov 22, 2006
Glasgow Evening Times,The court was then told by the health board's lawyer the previous decision not to prescribe the drug Laronidase would be reviewed.

BioMarin Announces US Launch of Orapred ODT Through Alliant ...  29 Aug 2006
...for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I ... -PR Newswire

Brave little Aiden's still full of bounce  Aug 14, 2006
Parents are also angry that the Scottish Medicines Consortium has not recommended laronidase, a treatment for Hurler's disease available in England, because it ... -Scotsman

BioMarin Announces Second Quarter 2006 Financial Results  Aug 2, 2006
Net sales of Aldurazyme(R) (laronidase), an enzyme replacement therapy for mucopolysaccharidosis I, (MPS I) by BioMarin/Genzyme LLC increased 23 percent to ... -PR Newswire

Alfimeprase to succeed Genentech's alteplase?  Aug 2, 2006
Other enzyme products followed, including Aldurazyme (laronidase), from Genzyme and BioMarin Pharmaceutical, in 2003, and, in 2005, Naglazyme (galsulfase) from ... -Nature.com (subscription)

BioMarin Announces Second Quarter 2006 Financial Results  Aug 2, 2006
Net sales of Aldurazyme® (laronidase), an enzyme replacement therapy for mucopolysaccharidosis I, (MPS I) by BioMarin/Genzyme LLC increased 23 percent to ... -Yahoo! News

Delivers Solid Earnings Growth Based on Strong Top-Line ...  Jul 18, 2006
Sales of Aldurazyme® (laronidase) enzyme replacement therapy for patients with MPS I were $23.5 million in the second quarter, a 23 percent increase from ... -Oxfordshire Bioscience Network

BioMarin Initiates Phase 2 Clinical Study Of 6R-BH4 In Poorly ...  Jul 7, 2006
...for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I ... -Medical News Today

Genzyme Reports Second-Quarter Financial Results  Jul 12, 2006
Sales of Aldurazyme(R) (laronidase) enzyme replacement therapy for patients with MPS I were $23.5 million in the second quarter, a 23 percent increase from ... -Drug Newswire



Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006 ...  May 11, 2006
...for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I ... - Genetic Engineering News

BioMarin Announces First Quarter 2006 Financial Results  May 3, 2006
Net sales of Aldurazyme(R) (laronidase), an enzyme replacement therapy for mucopolysaccharidosis I, (MPS I) by BioMarin/Genzyme LLC were $21.3 million for the ... - PR Newswire

BioMarin to Present at the Rodman and Renshaw 3rd Annual Global ...  May 8, 2006
...for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme® (laronidase) for mucopolysaccharidosis I ... - Yahoo! News

Genzyme Reports Financial Results for the First Quarter of 2006  Apr 19, 2006
Sales of Aldurazyme(R) (laronidase) enzyme replacement therapy for patients with MPS I increased 34 percent to $21.3 million in the first quarter, compared ... - MSN Money

FDA Approves Genzyme's Myozyme(R) for All Patients with Pompe ...  Apr 28, 2006
1 Gaucher disease; Fabrazyme® (agalsidase beta) for Fabry disease; and, in collaboration with BioMarin Pharmaceutical Inc., Aldurazyme® (laronidase) for MPS I ... - Yahoo! News

FDA Approves Genzyme's Myozyme for All Patients with Pompe Disease  Apr 28, 2006
Gaucher disease; Fabrazyme(R) (agalsidase beta) for Fabry disease; and, in collaboration with BioMarin Pharmaceutical Inc., Aldurazyme(R) (laronidase) for MPS I ... - PharmaLive.com





BioMarin Announces Closing of $295 Million Concurrent Public ...  Mar 30, 2006
...for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme(R) (laronidase) for mucopolysaccharidosis I ... - PR Newswire

BioMarin and Alliant Pharmaceuticals Announce North American ...  Mar 15, 2006
...for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I ... - Yahoo! News



BioMarin Announces Fourth Quarter and Year-End 2005 Financial ...  Feb 23, 2006
Net sales of Aldurazyme(R) (laronidase), an enzyme replacement therapy for mucopolysaccharidosis I, (MPS I) by BioMarin/Genzyme LLC increased 36 percent to ... - PR Newswire,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional